Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think that Inovio is still in good shape long term. The news the other day about the Malaria vaccine is only the beginning. http://biotechpicklist.blogspot.com/2013/08/inovio-shows-great-results-in-malaria.html This company has results coming in mid 2014 on its cervical dysplasia phase 2 results. Patience is needed in this one!
Celldex Expands ReACT trial in Recurrent Glioblastoma http://biotechpicklist.blogspot.com/2013/08/celldex-expands-phase-2-study-in.html
July 22nd was application date sent in so 6 to 8 weeks after that. Could be possibly last week of August or beginning September!
I think the pop was huge today, but they had to dilute the company is in good shape. Anyways check out this article on OPXA http://biotechpicklist.blogspot.com/ I think that the company will continue to pass phase 2 eventually and this will trade higher. Good luck to all longs!
The CEO continues to accumulate more shares RXIID every week. I want to see this kind of buying everyday! http://rxii.ir.edgar-online.com/fetchFilingFrameset.aspx?FilingID=9436659&Type=HTML
You want proof??? Here is proof since you have asked so nicely for it!
Cell Biosystems Inc. run by David KOOs name changed to Tulip Biomed Inc. back in 2004. now if you go to link of Tulipbiomed guess what you get this http://www.tulipbiomed.com./ = not found
so before BMXP was formed in 2006 it was known as Bio-matrix Scientific group! Shown here on Bloomberg Businessweek.
As of June 24, 2008, BMXP Holdings, Inc. was acquired by Freedom Environmental Services, Inc., in a reverse merger transaction. BMXP Holdings, Inc. is a development stage company that engages in the research, development, and commercialization of medical devices and monitoring systems. It develops products in the areas, such as stem cell cryogenics, instrumentation for stem cell research and tissue management, noninvasive bio-systems monitoring and measuring devices, and niche medical device instrumentation. The company was formerly known as Bio-Matrix Scientific Group, Inc. and changed its name to BMXP Holdings, Inc. in August 2006. The company is based in Delmont, Pennsylvania."
I can post many more instances, but you get the picture. Koos is just forming shell company after shell company and diluting shareholders. now read this more proof!
http://investorshub.advfn.com/Tasco-Holdings-THII-6297/
you asked for proof of the fraud and I posted it and you are welcome!
Yes it is from the common stock and little but if they continue to add everyday like this it should be seen as a positive.
I will be honest I used to be against you about the company, but I did more research and found out what other companies Koos has been a part of. Look it up its easy to see he forms a company and then dumps it after. YOu can try to look up all these previous companies but some you won't find anymore.
Dr. David R. Koos, Ph.D., DBA., has been Chairman of the Board, Chief Executive Officer, Acting Chief Financial Officer and Secretary of Bio-Matrix Scientific Group Inc., an affiliate of Regen BioPharma Inc., since June 19, 2006. Dr. Koos has been the President of Regen BioPharma Inc. since May 29, 2013. He has been the Chief Executive Officer, President and Secretary of Entest Biomedical, Inc., since June 19, 2006 and serves as its Principal Financial Officer. Dr. Koos serves as Chief Executive Officer of BMSN at Entest Biomedical, Inc. He has been the Chairman of the Board, Chief Executive Officer, President, Secretary, and Acting Chief Financial Officer of Entest CA since August 22, 2008. He has been the President, Chief Executive Officer, Secretary, Chief Financial Officer and Principal Accounting Officer of JBCC since June 19, 2009. Dr. Koos has been the President and Managing Director of Venture Bridge Inc. since November 21, 2001. He is the Founder and has been President and Managing Director of Cell Source Research Inc. since December 5, 2001. He served as the Chief Financial Officer, Principal Accounting Officer and Treasurer of Entest Biomedical, Inc. from June 19, 2006 to April 2010. He served as the Principal Accounting Officer and Treasurer of Bio-Matrix Scientific Group, Inc. and served as its President since June 19, 2006 and its Chief Operating Officer June 2009. Dr. Koos served as the Chief Executive Officer, Acting Chief Financial Officer, Principal Accounting Officer, Chief Financial Officer and Secretary of Frezer Inc. from May 2005 to February 2007. He served as Secretary of Tulip BioMed Inc. until December 1, 2003. He has been involved with investment banking, venture capital, and investor relations for over 20 years. He has worked with several major Wall Street investment banks. He has an extensive involvement with Initial Public Offerings, Secondary Offerings and Private Placements, greatly benefiting Bio-Matrix Scientific Inc. Dr. Koos served as the Chairman of the Board, Chief Financial Officer and Secretary of Cell Bio-Systems Inc. from July 17, 2003 to December 1, 2003. He served as the Chief Executive Officer, Acting Chief Financial Officer and Chairman of BMXP Holdings Inc. from December 6, 2004 to June 2008 and also served as its Secretary since December 6, 2004. He served as the Chief Executive Officer, Secretary, Acting Chief Financial Officer and Chairman of BMSG since December 6, 2004. Dr. Koos served as the Chief Executive Officer and Chairman of Storage Suites America since December 2004. Dr. Koos served as Vice President of Investments at Sutro & Co., Everen Securities and Dean Witter. He served as Registered Representative of Amerivet Securities Inc. from March 31, 2004 to February 2008. He has been Chairman of Entest Biomedical, Inc. since June 19, 2006. He has been the the Chairman of the Board of Bio-Matrix Scientific Group, Inc. since June 14, 2006. Dr. Koos served as the Chairman of the Board of Frezer Inc. from May 2005 to February 2007. Dr.Koos served as the Chairman of Tasco Holdings International Inc. since July 1, 2006. He has been a Director of Entest Biomedical, Inc. since June 19, 2006. He has been a Director of JBCC since June 19, 2009. He served as a Director of Tasco Holdings International Inc. since July 1, 2006. He served as a Director of Tulip BioMed Inc. until December 1, 2003. He served as a Director of Frezer Inc. from May 2005 to February 2007. He served as a Director of BMXP Holdings Inc. He is working towards a Ph.D. in Financial Management at Northcentral University. Dr. Koos received his first doctorate is a Doctor of Philosophy degree a in Economic Sociology from the University of California Riverside in 1983. He holds a Ph.D in Economic Sociology in September 2003 and Doctor of Business Administration (DBA), with a specialization in Corporate Finance in 2003 from Atlantic International University. Dr. Koos received a Master of Arts degree in Sociology from the University of California, Riverside, California in 1983."
So as I used to be against you paris I see that you do have a point!
Inovio has the pipeline to succeed. We will be getting the results from the Cervical Dysplasia phase 2 trial in Q1 of 2014. But it seems investors are now realizing the potential of this company thus the quick rise in share price. Also don't forget we have Leukemia phase 2 data update this year. INO is a good long term hold!
Good to see insiders keep loading up. Last week CEO bought shares, today August 5, 2013 another Director Robert J. Bitterman bought shares.
CEO bought last week, today Robert J. Bitterman Director bought some shares. Good to see insiders loading up shares! http://rxii.ir.edgar-online.com/fetchFilingFrameset.aspx?FilingID=9435203&Type=HTML
But look at other biotech stocks listed on NASDAQ or NYSE when they put in an IND they show preclinical work and are approved immediately for testing. The fact that BMSN has to submit more data is not good as the FDA was not satisfied with current data! IMUC submitted their IND and got approval by FDA immediately after only one submission.
But look at other biotech stocks listed on NASDAQ or NYSE when they put in an IND they show preclinical work and are approved immediately for testing. The fact that BMSN has to submit more data is not good as the FDA was not satisfied with current data! IMUC submitted their IND and got approval by FDA immediately after only one submission.
Why this drop if Perkins Trust Fund and World Funds trust are buying RXII? Look at new sec filing on the news: http://ih.advfn.com/p.php?pid=nmona&article=58604227
Insider buying by CEO form posted 4 hours ago seen here:
http://ih.advfn.com/p.php?pid=nmona&article=58589308
Saturday Article from Wall Street Cheat Sheet on RXII "RXI Pharma Hopes For A Quick Breakthrough" http://wallstcheatsheet.com/stocks/rxi-pharma-hopes-for-a-quick-breakthrough.html/?ref=YF
Just to add one more thing from the CEO of RXII in interview Excaliard (spinoff of ISIS acquired by Pfizer) reported positive results in their phase 1 trial of 30% to 40% reduction of scarring and they used higher dosing.
RXII achieved higher than excaliard drug at 42%, but RXII used a lower dose regimen than Excaliard. Take note of that RXII got better reduction of scarring with a lower dose than Excaliards drug. Meaning with the additional cohorts added to multi dose RXII's phase 1 drug will go way higher than Excaliards phase 1.
Also don't count out the reverse split I'm sure the CEO did it for a reason. Their was probably high demand for institutions to buy in after symposium, but they can't when the stock trades for .15 cents. Now at this price and an uplisting to Nasdaq lots of institutions can start building a position.
Phase 2 is starting by October. Actually two phase 2 trials are starting by 4th quarter 2013, and a 3rd phase 2 trial is starting 1st quarter 2014. Also we are gonna get additional data for multidose phase 1b trial, because they added 2 more cohorts as an extension with higher dosing. Also plenty of catalysts because each of the 3 phase 2 trials will be updated at months 3, 6, and 9 with results.
Also we already saw efficacy of the drug. I mentioned this before most other biotech you don't get to see full efficacy until phase 2 , but with anti scarring we can see it early. It either reduces scarring more than placebo or it doesn't! Hope this helps you understand good luck to all longs in RXII!
TD ameritrade just updated in my account for new symbol and shares for RXIID
I think the CEO is wise. He is doing the right thing! Now if we uplist to NASDAQ we can get big institutions to start investing in the company. The best thing I hear is that the company believes in the tech so much that is the reason for the uplisting. otherwise they could just stay in the penny stock area being shorted by Knight capital!RXII is a long term winner!
Well it seems yahoo finance shows RXIID up about 15%!
In my TD account it shows a Cusip # but no symbol yet! I think they are still working on fixing it!
Amilewski3 I'm happy what you are doing for new investors, but you have to understand their in denial. As I'm typing this the stock price is now down 18% and dropping and I'm sure they will say it is a good thing. That's what happens when you are in shock and denial! because you have lost so much money! The first step is admitting you need help!
If I was CEO of ADVAXIS there were better choices. Do the reverse split before the good news at ASCO. Secondly don't hide the CIN 2/3 results from your investors be upfront and honest, don't bury it in an 8-k hoping nobody will read it. Just so many things that went wrong here. I wish people the best and hope it recovers, and hope people recover their money here but it is a wishful thinking right now!
you know what I think you may be on to something. Reason I say that is because of the CTO order or confidential treatment order. They may probably announce a jv or partnership after reverse split. I guess I can see your point as to wanting to uplist to NASDAQ or else they could have waited till after phase 2 to uplist. Very interesting analysis.
If management was more forthcoming the stock price would be higher. I told people many times about Tom moore's past but they kept putting me off, people were warned. Tom Moore got fined by SEC for making up false statements. The only reason he didn't go to jail is because he settled with money.
The whole premise was biopure where Tom Moore CEO and other executives claimed how FDA approved them to start trials, in actuality the FDA told them to stop. They never told investors this, and investors lost a lot of money. Why would people put money to work into a company that Tom Moore is running again?
Lastly I will leave you with this. Remember the failed CIN 2/3 trial U.S.? Instead of putting out a press release to tell shareholders about this, they buried it in an 8k which they knew not many would read. Why weren't they honest with investors and put out a press release? Why Hide it in an 8k? Too many problems with this company I would stay away
All OTC biotechs suffer the same fate. Manipulation by Knight capital group. did you see for 2 months how RXII fluctuated from between .19 cents to .20 cents per share? notice on both dates of positive results 50% or more shorted the stock? That's why you are right. I think once we are on the Nasdaq capital market this manipulation will be gone.
I see what you are saying Notebook but think of it this way. RXII right now is at 333 million shares outstanding which is easy to manipulate, after the reverse split we should be somewhere between 25 million shares to 50 million shares. Much harder to manipulate.
why wouldn't the NASDAQ approve? They were on the OTCQX and had all financials in order. I see your point though, but I still think that upping the share price is the better thing to do.
Alnylam doesn't have a drug out how is it trading at $43 per share??? The market is strange , there is no rational thinking on the stock market. Also GALE has one trial in phase 3 and their pipeline is not that big.
RXII has anti scarring $4 billion market, plus can to to eye indications afterwards which the ophthomology pipeline totals $10 billion alone. so $4 billion anti scarring + $10 billion otphthomology puts it at $14 billion dollars valuation.
It is uplisting on Wednesday how will it get cheaper explain???
sure it does. Look at the 2 positive results we got for phase 1a and phase 1b. Both good results yet we got shorted completely. The OTC has too much manipulation in it. Many companies are suffering the same fate in the OTC>
As for benefit? Basically now all institutions can invest in RXII now. Where as before none could. That's a huge benefit. This means also when we get news we won't be shorted entirely.
If you go back to phase 1 single dose results we got good results, but 50% of the 2 mil volume we got that day was shorted. Too much manipulation on the OTC so I think the uplisting is the best scenario possible for RXII.
You do realize that is uplisting to the NASDAQ capital Market right??? New share price will be $4.50 or so! I think it's better because it will allow more institutions to invest in it. Anti scarring is a huge market, and I think they will get more interest.
This CEO though is amazing. He was able to take RXII from OTC pink sheet , to OTCQX, to NASDAQ capital market is less than 2 months or so.
http://finance.yahoo.com/news/rxi-pharmaceuticals-announces-application-nasdaq-135800009.html
Believe it or not your own DD should be considered. I had clowns poking fun of me and others owning PCYC back when it was under $1 per share. Where are those clowns now? probably feeling a lot of guilt!
Point is invest in what you like and ignore all the noise! RXII IMO will either A.) Be bought out, or B) get RXI-109 to market. Either way RXII will be a good long term stock to own!
Of course RXII got offers! My bet is they got offers from big pharma, but the problem is now in phase 1 they would have gotten terrible milestone deals.
Also Pfizer offered a lot of money to buy out Excaliard because of it anti scarring drug EXC-001. So I'm pretty sure another big pharma will either try to make a deal or bid for RXI pharmaceuticals to counter Pfizer.
Of Course, because SPPI scooped up all the shares! So how could you trade any shares? It's a done deal! Anyways I looked at this stock a year back and almost bought it, but got INO and RXII instead. But I hope shareholders recover there money somehow eventually! Nobody likes to see others lose money!
Guys check out this interesting fact here. That day we dropped 31% was shorts covering. You ask how do I know? Because you can tell they exited their position. Look 30 days the day of the presentation and one day after the presentation. Then look the last 2 days yesterday and today. Notice the difference I sure did, and I'm sure you can too for RXII.
Jul 17 6.58% 0.17 0.15 0.16 -5.88% 64,942 987,168
Jul 16 7.51% 0.17 0.16 0.17 0.00% 56,855 757,496
Jul 15 27.15% 0.19 0.12 0.17 -10.53% 713,482 2,628,094
Jul 12 48.69% 0.21 0.19 0.19 0.00% 699,601 1,436,950
Jul 11 53.30% 0.21 0.19 0.19 0.00% 1,129,492 2,119,303
Jul 10 72.41% 0.20 0.19 0.19 0.00% 596,768 824,141
Jul 09 33.49% 0.20 0.19 0.19 -5.00% 217,874 650,627
Jul 08 48.82% 0.20 0.19 0.20 +5.26% 429,597 879,938
Jul 05 60.07% 0.20 0.19 0.19 0.00% 283,593 472,137
Jul 04 0% 0.19 0.19 0.19 0.00% 0 0
Jul 03 62.11% 0.19 0.19 0.19 0.00% 87,256 140,480
Jul 02 53.20% 0.20 0.19 0.19 -5.00% 110,769 208,216
Jul 01 57.29% 0.20 0.19 0.20 +5.26% 397,123 693,159
Jun 28 55.68% 0.20 0.19 0.19 -5.00% 119,175 214,019
Jun 27 60.48% 0.20 0.19 0.20 +5.26% 308,391 509,941
Jun 26 61.70% 0.20 0.19 0.19 0.00% 209,659 339,815
Jun 25 51.36% 0.20 0.19 0.19 0.00% 127,537 248,331
Jun 24 43.58% 0.20 0.19 0.19 -5.00% 153,964 353,293
Jun 21 40.97% 0.20 0.19 0.20 0.00% 274,981 671,123
Jun 20 27.76% 0.20 0.19 0.20 0.00% 143,316 516,239
Jun 19 55.42% 0.20 0.20 0.20 0.00% 552,032 996,028
Jun 18 57.89% 0.20 0.19 0.20 0.00% 93,250 161,085
Jun 17 57.39% 0.20 0.19 0.20 NA 102,437 178,492
Do you see it? short interest after that huge drop on Monday dropped from being 60% short daily volume each day down to 7% short volume each day! The evidence is clear folks the shorts covered!
Northwest biotherapeutics did it right. As soon as they did the reverse stock split they uplisted to the NASDAQ at the same time. That's what management should have done. Waited to get NASDAQ requirements then uplist.
are you talking about this?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46978308
manipulation is always rampant, but just keep the eye on the prize phase 2 results later down the line. They will be forced to cover eventually!
RXII dropped to .12 then quickly jumped back to .17 in an instant. somebody loaded up to take it higher. It didn't get there on its own! you will not see .10 that's wishful thinking!
Guys the company is doing good. This is a long term stock, if you want instant satisfaction trade Tesla, or something like that.
The company is on track and there is still plenty of time to run. The company is even running 2 additional cohorts for phase 1b multi dose study. They are testing a higher level dose for phase 1 since there was no toxicity with 3 doses. They could go to 4 or 5 doses over 3 months and still have good safety, plus increased efficacy.
Also phase 2 trials are coming fast. Two of the phase 2 trials are starting Q4 2013, this year. The 3rd phase 2 trial is set for Q1 2014. Also here are the catalysts that I'm talking about from Life Sci advisors.
? 3Q 2013 – Two expansion cohorts to enroll in multi-dose Phase I trial for RXI-109.
? 4Q 2013 – RXI-109 Phase II trial in breast surgery scar revision patients.
? 4Q 2013 – RXI-109 Phase II trial initiation in abdominal scar revision patients.
? 1Q 2014 – RXI-109 Phase II trial for keloids expected to commence.
? 2H 2014 – Expected IND filing for RXI-109 for ophthalmological indications
Don't forget also that those phase 2 trials will update at months 6, and 9 so we will get reports of efficacy while the trials are running.
Short selling attack in RXIi today was for institutions to get cheaper shares. By the way LifeSci Advisors just few mins ago released a report for the multi dose results. What perfect timing!
http://www.lifesciadvisors.com/clientinfo/rxi/RXi__Analyst_Day_7-15-13__clientinfo.pdf?utm_source=EmailDirect.com&utm_medium=Email&utm_campaign=RXi+Analyst+Day+Note+Campaign